#BSR24 👉BSR guidelines on Sjögren 🔸USS of salivary glands is useful but does not substitute biopsy 🔸Measure ENA if ANA is negative 🔸Biomarkers for lymphoma development 🔸Biomarkers that predict disease progression and extra-glandular disease #sjogren

Great session this morning on the massively overlooked topic of menopause in rheumatic disease

A very well deserved award for Rudi Shukla 👏👏 👏

🚨 Looking forward to hearing about health inequalities in #sle and #NIEAA cohort 📍 Room 4 #BSR24 #ethnicitysig Sarah Dyball Ian N Bruce

Excellent presentation by Cristiana Sieiro Santos 👏 465 pregnancies from a single centre in 🇪🇸 across CTDs 🔴More adverse pregnancy outcomes (APOs) in SLE 🟠 Maternal mortality higher in SSc 🟡 aPL independent predictors of APOs 🟢HCQ protective across diseases

#bsr24 really important session on inclusivity. Highlighting the challenges around risk correction for ethnicity (also relevant for bone diseases) and explaining why GCA in poc is underreported. Thanks Puja Mehta BSR Association of Women in Rheumatology

Great talk on #JIA in adulthood from Lianne Kearsley-Fleet 2/3 of patients are followed up in adult services and associated with 🟢 Older age of diagnosis ♀️ Gender 👁️ Uveitis ⬇️ Levels of social deprivation ❓ Losing those from deprived groups to follow up

🤰"Will I have a healthy baby?" An excellent summary of the evidence on neurodevelopmental outcomes of individuals born to mothers with rheumatic diseases from Laura Andreoli Patient education and empowerment is 🗝️ #BSR24

Evidence that unconscious bias affects the care we give 🇺🇸 Don't think this is limited to the USA 🗣️ So important to reflect on our own personal biases but also the social structures we operate within

💥Significant proportion of CTD patients are excluded from Ph3 clinical trials 💥Classification criteria may take several years to be adopted into trial protocols 💥Stringent trial eligibility may lead to poor generalisability for real-world patients 👇 sciencedirect.com/science/articl…

✅ TODAY is the official start of #EULAR2024 ✨ with the convergence of 12k+ #Rheumatology specialists & researchers from ALL over the world. The full program of this EULAR event is truly AMAZING, and for #Lupus there will be 33 oral presentations and almost 200 posters 👍

Day 1 at #EULAR2025 🚨 Catch me presenting on real-world outcomes of NPSLE treated with rituximab 16.50-17.00hrs in C8 🔵Also looking forward to hearing CAR-T and novel agent trial updates

Efficacy of rituximab in neuropsychiatric #SLE : data from the BILAG biological register. #EULAR2024 MS

Great presentation from Jack Arnold on novel reclassification of ANA+ RMD patients ❔could this be used to explain heterogeneity in clinical response to treatment in future trials❔

Important work from Sarah Dyball ❕Around half of SLE patients demonstrating a clinical improvement failed actually FEEL better psychologically

🫁 Looking forward to answering some clinical questions current guidelines don't cover 🔵 Lots of work ahead!

Now it's the turn of #rheumatology #HealthcareProfessionals in the #UK to share your views and current practice on #ClinicLetter writing This BSR funded survey is open to all #doctors #nurses #AHPs #pharmacists 👀bit.ly/W2Phcpsurvey Please share!

Excellent presentation from Dr Stevie Shoop-Worrall on involving patients to interpret findings from complex statistical modelling at #UKRIME